language_icon
EN
HI

Dr Lal Pathlabs. Share price

LALPATHLAB

1367.2

0.00 (0.00%)
NSE
BSE
Last updated on 30 Apr, 2026 | 15:52 IST
Today's High

1400.00

Today's Low

1363.00

52 Week Low

1272.60

52 Week High

1770.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Dr Lal Pathlabs Chart

Dr Lal Pathlabs. Share Key Metrics

Volume
2.96 L
Market Cap
22908.12 CR
LTQ@LTP
50@1367.20
ATP
1373.53
Var Margin
13.78 %
Circuit Range
1118.3-1677.3
Delivery %
56.22 %
Value
40.61 CR
ASM/GSM
No
Market Lot
1

Summary

Dr Lal Pathlabs. share price stands at ₹1367.2 at 30 Apr, 2026 | 15:52. The stock Dr Lal Pathlabs. intraday movement has stayed between ₹1363.00 and ₹1400.00, while on a 52-week basis it has fluctuated from ₹1272.60 to ₹1770.00.
In terms of trading activity, Dr Lal Pathlabs. has recorded a volume of 295679 shares. The Dr Lal Pathlabs. has a market cap of ₹167555020. The stock’s Average Traded Price (ATP) stands at ₹137353, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 50, 136720.
The Dr Lal Pathlabs. operates within a circuit range of ₹1118.3-1677.3 – ₹1118.3-1677.3, with a Value of ₹40.61 CR. The Delivery Percentage for the day is 56.22%. Additionally, Dr Lal Pathlabs. currently falls under the No framework, and trades with a market lot size of 1.

Dr Lal Pathlabs. Fundamentals

View More
P/E Ratio

45.43

P/B Ratio

9.14

Div. Yield

1.5

Sector P/E

54.3

Sector P/B

-16.17

Sec. Div. Yield

1.89

Dr Lal Pathlabs. Resistance and Support

Pivot 1376.73

Resistance

First Resistance

1390.46

Second Resistance

1413.73

Third Resistance

1427.46

Support

First Support

1353.46

Second Support

1339.73

Third Support

1316.46

Dr Lal Pathlabs. Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

53.21%

Mutual Fund

18.62%

Insurance

2.33%

Foreign Institutional Investors

17.18%

Domestic Institutional Investors

0.3%

Retail

8.35%

Others

0.01%

Total Promoters
MAR '26
53.21%

Dr Lal Pathlabs. Corporate Actions

DateAgenda
2026-04-30Audited Results & Final Dividend
2026-01-30Quarterly Results & Interim Dividend
2025-10-31Qtr Results
2025-07-31Quarterly Results
2025-04-25Audited Results & Final Dividend
2025-01-30Quarterly Results

Dr Lal Pathlabs. News

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

Dr. Lal Path Labs has completed the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited. This makes SDCPL a wholly-owned subsidiary, strategically expanding the company's diagnostic network.
May 01 2026 19:05:00

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Dr. Lal Path Labs has made available the audio recording of its earnings conference call for Q4 & FY26. Investors and analysts can access the recording on the company's website for review.
Apr 30 2026 19:04:00

Dr. Lal Path Labs Ltd.

DR. LAL PATH LABS board approved the re-appointment of Dr. Arvind Lal as Executive Chairman and Whole-Time Director for a period of five years. This re-appointment will be effective from April 1, 2027, and is subject to the approval of shareholders at the upcoming Annual General Meeting.
Apr 30 2026 18:04:00

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs board recommended a final dividend of Rs. 4 per equity share for the financial year ended March 31, 2026. The record date for this dividend is June 26, 2026.
Apr 30 2026 18:04:00

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs announced the incorporation of a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE. This entity will focus on strategic investments in diagnostics and allied activities, including potential acquisitions and joint ventures, marking an international expansion.
Apr 30 2026 18:04:00

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Dr. Lal Path Labs announced FY26 consolidated financial results. Revenue increased 12.2% YoY to Rs.2,763 Cr, and net profit grew 3.6% YoY to Rs.510 Cr. However, Q4 net profit declined by 15.1% YoY.
Apr 30 2026 16:04:00

Dr. Lal PathLabs Ltd - 539524 - Incorporation Of A Wholly Owned Subsidiary Company

Dr. Lal Path Labs' board approved Q4 FY26 financial results and recommended a final dividend of Rs. 4 per share. The board also approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited for up to Rs. 20 crore and the incorporation of a wholly-owned subsidiary in Dubai, UAE, for international expansion.
Apr 30 2026 15:04:00

Dr. Lal PathLabs Ltd - 539524 - Senior Management Personnel (SMP)

Dr. Lal Path Labs' board approved Q4 FY26 financial results and recommended a final dividend of Rs. 4 per share. The board also approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited for up to Rs. 20 crore and the incorporation of a wholly-owned subsidiary in Dubai, UAE, for international expansion.
Apr 30 2026 15:04:00

Dr. Lal PathLabs Ltd - 539524 - Re-Appointment Of M/S Ernst & Young LLP (EY) As Internal Auditors And M/S A.G. Agarwal & Associates As Cost Auditors

Dr. Lal Path Labs' board approved Q4 FY26 financial results and recommended a final dividend of Rs. 4 per share. The board also approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited for up to Rs. 20 crore and the incorporation of a wholly-owned subsidiary in Dubai, UAE, for international expansion.
Apr 30 2026 15:04:00

Dr. Lal PathLabs Ltd - 539524 - The Record Date For The Purpose Of Payment Of Final Dividend Shall Be June 26, 2026

Dr. Lal Path Labs has set June 26, 2026, as the record date for its final dividend. The board recommended ₹4 per equity share for FY26, subject to shareholder approval at the upcoming AGM.
Apr 30 2026 15:04:00
Read More

About Dr Lal Pathlabs.

NSE : 11654  
BSE : 539524  
ISIN : INE600L01024  

Late Dr. Major S.K. Lal commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory' pursuant to a partnership deed dated March 21 1975 with the partnership deemed to have commenced from December 1 1974. The partnership firm was formed to provide pathology services under the name ?Central Clinical Laboratory? and to maintain a blood bank for the supply of blood to patients and hospitals under the name ?Blood Transfusion Centre? both to be undertaken at the Registered Office of the Company. On December 5 1977 following the demise of Late Dr. Major S.K. Lal Late Ms. Vimla Lal wife of Late Dr. Major S.K. Lal was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal?s demise Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2 2007. Accordingly as on date Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as ?Dr. Lal PathLabs Private Limited? a private limited company under the Companies Act 1956 with a certificate of incorporation granted by the RoC on February 14 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7 2015. Consequently the name of the Company was changed to ?Dr. Lal PathLabs Limited? and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19 2015.Awards and accreditations :2001-Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services including in clinical trials. 2002-Fully accredited by the College of American Pathologists? Laboratory Accreditation Program. 2008-Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010-Franchisor of the Year in healthcare at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012-Diagnostic Service Provider Company of the Year by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013-Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014-Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories ? Requirements for Quality and Competence" for medical testing for National Reference Laboratory. 2015-Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon Haryana India. Major events and milestones :2005 & 2007-Investment by WestBridge I Investments Holdings. 2008-Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013-Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013-Investment pursuant to purchase of shares by WestBridge Crossover Fund LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014-Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015-Amalgamation of Sanya Chemicals Private Limited Amolak Diagnostics Private Limited Medex Healthcare Private Limited Medicave Diagnostic Centre Private Limited Medicave Medical Systems Private Limited and the Company.

Read More

Dr Lal Pathlabs. Management

NamePosition
Vinay GujralCompany Secretary & Compliance Officer
Arvind LalChairman
View More

Dr Lal Pathlabs. FAQs

The Buying Price of Dr Lal Pathlabs. share is 1367.2 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Dr Lal Pathlabs. stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Dr Lal Pathlabs., choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Dr Lal Pathlabs. shares is 45.43. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Dr Lal Pathlabs. shares is 9.14. Useful to assess the stock's value relative to its book value.

To assess Dr Lal Pathlabs.’s valuation compare Sector P/E, P/B which are 54.3 & -16.17 with sector averages, along with growth rates and financial metrics.

The Market Cap of Dr Lal Pathlabs. is 22908.12 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Dr Lal Pathlabs. share price is 1770.00 & 1272.60. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Dr Lal Pathlabs. belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost